Vitt Daniel 4

What Happened

• Director Daniel Vitt was granted a derivative award on June 29, 2026: options covering 445,000 shares of IMMUNIC common stock. The Form 4 reports the transaction as an award (transaction code A) with a reported price of $0.00, indicating a granted option-based award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-29 (filed same day — timely filing).
• Award size: options to purchase 445,000 shares (reported price $0.00).
• Shares owned after transaction: not specified in this Form 4.
• Footnote F1: The grant represents options conditionally approved by the Board and subject to an amendment to the 2019 Omnibus Equity Incentive Plan; stockholder approval for the amendment was obtained at IMMUNIC’s 2026 Annual Meeting on June 29, 2026.
• Footnote F2: Vesting schedule — 25% vests on April 2, 2027, with the remaining 75% vesting in equal monthly increments over the next 36 months.
• Transaction type: derivative award (options). No immediate sale or cash exercise reported.

Context

• This is an equity compensation award, not a market purchase or sale. The options vest over time, so they are not immediately convertible into tradable shares until vested and exercised according to plan terms. Such grants are common for executives/directors and are intended for retention and alignment with shareholders; they do not by themselves signal near-term buying or selling.